MET
MET, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase encoded by the MET proto-oncogene. Its activation by hepatocyte growth factor influences cell survival, embryogenesis, migration and invasion, and the gene is frequently altered in cancer. Browse Assay Genie's current range of MET research reagents below, or read on for the biology behind the target.
MET is the receptor for hepatocyte growth factor (HGF). The protein belongs to the protein kinase superfamily and the tyrosine protein kinase family, and it catalyses tyrosine phosphorylation (EC 2.7.10.1). Binding of HGF induces dimerisation and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. UniProt also records a role for MET as a receptor for Listeria monocytogenes internalin InlB, through which the pathogen enters cells.
The MET gene encodes a preproprotein that is proteolytically processed into alpha and beta subunits. These are linked by disulfide bonds to form the mature receptor. Further processing of the beta subunit produces the M10 peptide, which has been shown to reduce lung fibrosis. UniProt lists the protein as occurring in both membrane and secreted forms. HGNC places it in the IPT domain containing group and the MET proto-oncogene, receptor tyrosine kinase family.
The gene was previously named met proto-oncogene, and the symbols HGFR, RCCP2 and DFNB97 are also in use. Mutations in the MET gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma and various head and neck cancers. Amplification and overexpression of the gene are also associated with multiple human cancers. This makes MET a frequent subject in studies of oncogenic signalling, invasion and tissue repair.
Mutation, amplification and overexpression of MET are linked to papillary renal cell carcinoma, hepatocellular carcinoma, head and neck cancers and other human tumours.
HGF binding drives MET dimerisation and activation, making the receptor a model for studying tyrosine kinase signalling in survival and migration.
MET activity contributes to cellular migration and invasion, relevant to studies of tumour spread and tissue remodelling.
MET has a role in embryogenesis, and its beta-subunit-derived M10 peptide has been shown to reduce lung fibrosis.
MET is a receptor tyrosine kinase that binds hepatocyte growth factor. Ligand binding induces dimerisation and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. It also serves as a receptor for Listeria monocytogenes internalin InlB.
MET is also called hepatocyte growth factor receptor (HGFR). Other symbols are RCCP2 and DFNB97, and the gene was previously named met proto-oncogene. The mature receptor consists of alpha and beta subunits joined by disulfide bonds, produced by processing of a preproprotein.
Yes. Mutations in the MET gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma and various head and neck cancers, and amplification or overexpression is seen in multiple human cancers. A rat ortholog, Met, exists; check the datasheet of any product for its validated reactivity.
The MET ligand HGF, together with other targets that have similar gene symbols but are not MET pathway members.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P08581; product specifications from Assay Genie datasheets.